Use of slow-acting symptomatic drugs in osteoarthritis. The effectiveness of the combination of glucosamine and chondroitin in the light of the evidence Review article
Article Sidebar
Published:
Mar 31, 2021
Keywords:
osteoarthritis, articular cartilage, celecoxib, chondroitin sulfate, glucosamine hydrochloride, safety
Main Article Content
Abstract
Treatment of osteoarthritis requires the use of drugs that will slow down the destruction of articular cartilage and reduce joint pain. Slow-acting symptomatic medications are often used in daily practice. The most frequently used and considered the most effective preparations are glucosamine and chondroitin. High-quality studies have shown that the combination of this both substances is effective in slowing the progression of the disease and reducing pain, and is also safe, even with prolonged use.
Article Details
How to Cite
Tłustochowicz , W. (2021). Use of slow-acting symptomatic drugs in osteoarthritis. The effectiveness of the combination of glucosamine and chondroitin in the light of the evidence. Medycyna Faktow (J EBM), 14(1(50), 110-115. https://doi.org/10.24292/01.MF.0121.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Scanzello C, Plaas A, Crow M. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008; 20: 565-72.
2. Managing osteoarthritis. NICE Pathway. Updated: 11 December 2020.
3. Haugen I, Englund M, Aliabadi P et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis. 2011; 70: 1581-6. http://doi.org/10.1136/ard.2011.150078.
4. Klimiuk PA, Kuryliszyn-Moskal A. Choroba zwyrodnieniowa stawów. In: Puszczewicz M. Wielka interna – reumatologia. 2nd ed. Medical Tribune Polska, Warszawa 2016.
5. Bos S, Slagboom P, Meulenbelt I. New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol. 2008; 20: 553-9.
6. Zhang W, Doherty M, Peat G et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69: 483-9.
7. Sakellariou G, Conaghan PG, Zhang W et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis. 2017; 76(9): 1484-94.
8. Lotz M, Martel-Pelletier J, Christiansen C et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013; 72: 1756-63.
9. Pottie B, Presle N, Terlain B et al. Obesity and osteoarthritis: more complex than predicted! Ann Rheum Dis. 2006; 65(11): 1403-5.
10. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390(10090): e21-33.
12. Kolasinski S, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2): 149-62. http://doi.org/10.1002/acr.24131.
13. Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
14. Bannuru R, Osani M, Vaysbrot E et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578-89.
15. Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 suppl 120(5): 135-40.
16. Calamia V, Mateos J, Fernández-Puente P et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014; 4: 5069. http://doi.org/10.1038/srep05069.
17. Reginster J-Y, Dudler J, Blicharski T et al. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9): 1537-43. http://doi.org/10.1136/annrheumdis-2016-210860.
18. McAlindon T, LaValley M, Gulin J et al. Glucosamine and Chondroitin for Treatment of Osteoarthritis. A Systematic Quality Assessment and Meta- analysis. JAMA. 2000; 283(11): 1469-75. http://doi.org/10.1001/jama.283.11.1469.
19. Reginster J-Y, Deroisy R, Rovati L et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357(9252): 251-6.
20. Bruyere O, Pavelka K, Rovati L et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16(2): 254-60.
21. Clegg D, Reda D, Harris C et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006; 354(8): 795-808.
22. Hochberg M, Martel-Pelletier J, Monfort J et al; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1): 37-44. http://doi.org/10.1136/annrheumdis-2014-206792.
23. Fransen M, Agaliotis M, Nairn L et al; on behalf of the LEGS study collaborative group: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015; 74(5): 851-8. http://doi.org/10.1136/annrheumdis-2013-203954.
2. Managing osteoarthritis. NICE Pathway. Updated: 11 December 2020.
3. Haugen I, Englund M, Aliabadi P et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis. 2011; 70: 1581-6. http://doi.org/10.1136/ard.2011.150078.
4. Klimiuk PA, Kuryliszyn-Moskal A. Choroba zwyrodnieniowa stawów. In: Puszczewicz M. Wielka interna – reumatologia. 2nd ed. Medical Tribune Polska, Warszawa 2016.
5. Bos S, Slagboom P, Meulenbelt I. New insights into osteoarthritis: early developmental features of an ageing-related disease. Curr Opin Rheumatol. 2008; 20: 553-9.
6. Zhang W, Doherty M, Peat G et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69: 483-9.
7. Sakellariou G, Conaghan PG, Zhang W et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis. 2017; 76(9): 1484-94.
8. Lotz M, Martel-Pelletier J, Christiansen C et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013; 72: 1756-63.
9. Pottie B, Presle N, Terlain B et al. Obesity and osteoarthritis: more complex than predicted! Ann Rheum Dis. 2006; 65(11): 1403-5.
10. Bruyere O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337-50.
11. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390(10090): e21-33.
12. Kolasinski S, Neogi T, Hochberg M et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2): 149-62. http://doi.org/10.1002/acr.24131.
13. Kloppenburg M, Kroon FP, Blanco FJ et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78(1): 16-24.
14. Bannuru R, Osani M, Vaysbrot E et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578-89.
15. Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 suppl 120(5): 135-40.
16. Calamia V, Mateos J, Fernández-Puente P et al. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014; 4: 5069. http://doi.org/10.1038/srep05069.
17. Reginster J-Y, Dudler J, Blicharski T et al. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017; 76(9): 1537-43. http://doi.org/10.1136/annrheumdis-2016-210860.
18. McAlindon T, LaValley M, Gulin J et al. Glucosamine and Chondroitin for Treatment of Osteoarthritis. A Systematic Quality Assessment and Meta- analysis. JAMA. 2000; 283(11): 1469-75. http://doi.org/10.1001/jama.283.11.1469.
19. Reginster J-Y, Deroisy R, Rovati L et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357(9252): 251-6.
20. Bruyere O, Pavelka K, Rovati L et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16(2): 254-60.
21. Clegg D, Reda D, Harris C et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006; 354(8): 795-808.
22. Hochberg M, Martel-Pelletier J, Monfort J et al; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75(1): 37-44. http://doi.org/10.1136/annrheumdis-2014-206792.
23. Fransen M, Agaliotis M, Nairn L et al; on behalf of the LEGS study collaborative group: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015; 74(5): 851-8. http://doi.org/10.1136/annrheumdis-2013-203954.